NO20001514L - Vitronectin-reseptor-antagonist - Google Patents

Vitronectin-reseptor-antagonist

Info

Publication number
NO20001514L
NO20001514L NO20001514A NO20001514A NO20001514L NO 20001514 L NO20001514 L NO 20001514L NO 20001514 A NO20001514 A NO 20001514A NO 20001514 A NO20001514 A NO 20001514A NO 20001514 L NO20001514 L NO 20001514L
Authority
NO
Norway
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
NO20001514A
Other languages
English (en)
Other versions
NO20001514D0 (no
Inventor
Dirk Andries Heerding
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20001514D0 publication Critical patent/NO20001514D0/no
Publication of NO20001514L publication Critical patent/NO20001514L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En forbindelse med formel (I) er beskrevet, som er en vitronectin-reseptor- antagonist og er nyttig for behandling av osteoporose, eller et farmasøytisk godtagbart salt derav.
NO20001514A 1997-09-24 2000-03-23 Vitronectin-reseptor-antagonist NO20001514L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5983297P 1997-09-24 1997-09-24
PCT/US1998/019949 WO1999015170A1 (en) 1997-09-24 1998-09-24 Vitronectin receptor antagonist

Publications (2)

Publication Number Publication Date
NO20001514D0 NO20001514D0 (no) 2000-03-23
NO20001514L true NO20001514L (no) 2000-03-23

Family

ID=22025570

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001514A NO20001514L (no) 1997-09-24 2000-03-23 Vitronectin-reseptor-antagonist

Country Status (13)

Country Link
EP (1) EP1017387A4 (no)
JP (1) JP2002528380A (no)
KR (1) KR20010024247A (no)
CN (1) CN1273529A (no)
AU (1) AU9577498A (no)
BR (1) BR9813208A (no)
CA (1) CA2303846A1 (no)
HU (1) HUP0003949A2 (no)
IL (1) IL135189A0 (no)
NO (1) NO20001514L (no)
PL (1) PL339413A1 (no)
TR (1) TR200000792T2 (no)
WO (1) WO1999015170A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20020072518A1 (en) * 2000-08-29 2002-06-13 Khanna Ish Kumar Bicyclic alphavbeta3 antagonists
BR0113671A (pt) * 2000-08-30 2004-01-06 Pharmacia Corp Antagonistas de integrina alfa v beta 3 gem-substituìda
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US20040136949A1 (en) 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
EP2428226A1 (en) 2001-10-22 2012-03-14 The Scripps Research Institute Antibody targeting compounds
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
MX2009007597A (es) 2007-01-18 2009-07-22 Merck Patent Gmbh Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
JP5359879B2 (ja) * 2007-11-16 2013-12-04 宇部興産株式会社 ベンズアゼピノン化合物
WO2009111679A2 (en) * 2008-03-06 2009-09-11 Smithkline Beecham Corporation Process
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
US20120095215A1 (en) 2009-03-30 2012-04-19 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of eye diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
BRPI1011206A2 (pt) 2009-05-25 2016-03-15 Merck Patent Gmbh administração contínua de ligantes de integrina para tratar câncer
CN103864765B (zh) * 2014-03-05 2016-02-10 天津药物研究院 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0762882A4 (en) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
JP2001501951A (ja) * 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション 骨形成刺激方法

Also Published As

Publication number Publication date
IL135189A0 (en) 2001-05-20
HUP0003949A2 (hu) 2001-10-28
NO20001514D0 (no) 2000-03-23
EP1017387A1 (en) 2000-07-12
JP2002528380A (ja) 2002-09-03
TR200000792T2 (tr) 2000-09-21
AU9577498A (en) 1999-04-12
EP1017387A4 (en) 2004-08-18
KR20010024247A (ko) 2001-03-26
BR9813208A (pt) 2000-08-22
CA2303846A1 (en) 1999-04-01
WO1999015170A1 (en) 1999-04-01
CN1273529A (zh) 2000-11-15
PL339413A1 (en) 2000-12-18

Similar Documents

Publication Publication Date Title
NO20001514L (no) Vitronectin-reseptor-antagonist
NO983002L (no) Vitronectin-reseptor-antagonister
NO20001515L (no) Vitronektin reseptor-antagonist
TR200000812T2 (tr) 2-metil-tieno- benzodiazepin formülasyonu.
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
GB0111523D0 (en) Chemical compounds
NL300344I1 (nl) Nucleotide-analogen
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
NO975975L (no) Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
BR9812340A (pt) Antagonistas de receptor de vitronectina
ATE359793T1 (de) 2-methyl-thieno-benzodiazepin formulierung
NO973652D0 (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
NO974400L (no) Kombinasjonspreparater inneholdende benazepril eller benazeprilat og valsartan
AP1534A (en) Vitronectin receptor antagonists.
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
NO990914L (no) Amorfe benzotiofener, fremgangsmÕter for fremstilling og fremgangsmÕter for anvendelse
WO1998031704A3 (en) Tachykinin antagonists
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists
WO2000007544A3 (en) Vitronectin receptor antagonists
HUP0100540A2 (hu) Szubsztituált oximok mint neurokinin antagonisták
NO306673B1 (no) Mellomprodukt for fremstilling av farmasöytisk aktiv forbindelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application